Ymir Genomics LLC (Ymir) and the Oregon Health & Science University (OHSU) Knight Cancer Institute today announced a licensing agreement and filed patent application that seeks to protect and promote newly-discovered high value urinary biomarkers for detecting cirrhosis and/or hepatocellular ...
Read More »Ymir Genomics and the OHSU Knight Cancer Institute to collaborate on urinary exosomal biomarkers
Ymir Genomics, LLC (Ymir) and the Knight Cancer Institute at Oregon Health & Science University, OHSU, today announced a strategic collaboration to develop urinary biomarkers that will help detect hepatocellular carcinoma (HCC) in at-risk patient populations. The collaboration will exploit ...
Read More »